Depo-Provera Brain Tumor Lawsuit: Case Details and Updates

Introducing the Depo-Provera Brain Tumor Lawsuit

Depo-Provera, a widely used injectable contraceptive, is under intense scrutiny due to mounting legal claims and medical research linking it to brain tumors. 

Plaintiffs allege that Depo-Provera’s active ingredient, medroxyprogesterone acetate, raises the risk of developing meningiomas – tumors that form in the membranes surrounding the brain and spinal cord.

Despite these risks being evident for decades, Pfizer, Depo-Provera’s manufacturer, has consistently failed to provide adequate warnings, leaving hundreds of thousands of women unaware of the dangers of routinely using the drug.

In March 2024, the British Medical Journal published groundbreaking research from French scientists revealing a 5.6-fold increase in the risk of meningiomas among women using medroxyprogesterone acetate for more than a year.

Shortly after, a California woman who had developed a meningioma after years of Depo-Provera use filed the first Depo-Provera lawsuit against Pfizer. The case triggered an influx of similar claims, alleging that the pharmaceutical giant failed to warn users of the dangers their products pose to a user’s health.

As with most product liability lawsuits, plaintiffs seek compensation for current and future medical bills, loss of earnings, emotional distress, and diminished quality of life. In certain cases, victims may also seek punitive damages to discourage Pfizer from similar negligence in the future.

Find Out if You Qualify For Compensation

Eligibility for a Depo-Provera lawsuit depends on several factors, with the most crucial being a documented diagnosis of meningioma following prolonged use of the drug. 

Given that the lawsuits are still in their early stages, the exact evidence needed for eligibility may vary, and each case will require an independent assessment by a legal expert.

Each claim is also subject to a statute of limitations, which defines the timeframe within which a lawsuit must be filed. Typically, this period begins from the date of diagnosis or when the potential link between Depo-Provera and the health condition was discovered.

If you or a loved one has experienced serious health issues linked to Depo-Provera and would like legal assistance in determining your eligibility, Tosi Law is here to provide the support you need.

With extensive experience in high-stakes product liability cases and a dedication to highly personalized client care, our firm is well-equipped to guide you on your journey toward justice and compensation.

Contact us today for a free, no-obligation consultation. 

Article Summary: What You Need to Know

1. Depo-Provera, an injectable contraceptive, is under legal scrutiny for its alleged link to brain tumors (called meningiomas) that can have severe impacts on the user’s health.
2. A 2024 study published in the British Medical Journal found a 5.6-fold increase in the risk of meningiomas among long-term Depo-Provera users, forming the backbone of plaintiffs’ claims.
3. Pfizer, the manufacturer of Depo-Provera, faces lawsuits alleging failure to warn users of known risks, inconsistent international warnings, and inadequate monitoring of adverse event reports.
4. Plaintiffs seek compensation for medical expenses, lost income, emotional distress, and diminished quality of life, with the potential for punitive damages to hold Pfizer accountable.
5. Statutes of limitations vary by state, and exceptions like the Discovery Rule may allow additional time for those who learned of the risks later. Acting quickly is essential to preserve your claim.
6. Tosi Law specializes in product liability cases and provides personalized representation to Depo-Provera users seeking justice. Contact us today for a free consultation to assess your case’s eligibility.

Latest Depo-Provera Lawsuit Updates

Ongoing 2024 – Expansion of Cases Across the U.S.

As of late 2024, more lawsuits have emerged in various states, each adding plausibility to claims that Pfizer failed to warn users of Depo-Provera’s risks. The growing number of cases soon after the watershed BMJ research paper and the first lawsuit being filed (in October 2024) suggest the potential for many new lawsuits in the coming months and years.

October 28, 2024: New Lawsuit Filed in California with Potential for Multidistrict Litigation

A new case, Kathleen Fazio v. Pfizer et al., was filed in the Central District of California. With several other filings in different jurisdictions, lawyers are considering consolidating the cases into multidistrict litigation (MDL) to streamline pretrial proceedings.

October 4, 2024: First Official Depo-Provera Lawsuit Filed

In the first official lawsuit, Kristina Schmidt v. Pfizer, a California woman claimed she developed a brain tumor after long-term Depo-Provera use. This case marks the beginning of formal litigation against Pfizer over the alleged health risks associated with Depo-Provera.

March 2024: BMJ Study Publishes Groundbreaking Research on Depo-Provera Risks

A major study published in the British Medical Journal in March 2024 uncovered a 5.6-fold increase in the risk of developing meningiomas among women who used Depo-Provera’s active ingredient, medroxyprogesterone acetate, for more than a year.

This study represents a pivotal moment in the case against Pfizer, serving as the first significant piece of credible scientific evidence linking the contraceptive to brain tumors. It has since become foundational to plaintiffs’ arguments, supporting claims that Pfizer may have had reason to suspect potential risks but failed to provide adequate warnings.

Table of Contents

TBC

A Closer Look at Depo-Provera and Its Health Complications

A Brief History of Depo-Provera 

Depo-Provera is an injectable contraceptive that has provided women worldwide with reliable long-term birth control for over three decades. Initially developed by Upjohn, a Michigan-based pharmaceutical company, Depo-Provera gained popularity due to its effectiveness and convenience, requiring only one injection every three months.

The drug’s path to FDA approval was complex. Initially, concerns over potential side effects, including bone density loss, delayed its approval. Following further research and debate over its health risks, the FDA eventually approved Depo-Provera for contraceptive use in 1992. 

In the early 2000s, Upjohn merged with Pfizer Inc., transferring the rights and responsibilities of Depo-Provera to one of the world’s largest pharmaceutical companies.

Potential side effects such as weight gain, menstrual changes, and, more recently, concerns over an increased risk of developing brain tumors have kept Depo-Provera under scrutiny from the medical community.

None of these potential health risks have significantly impacted the drug’s commercial success or its official FDA status, with the federal authority only intervening once in 2004 to mandate a warning on bone density loss.

How Does Depo-Provera Work?

At the core of Depo-Provera’s contraceptive action is medroxyprogesterone acetate (MPA), a synthetic hormone similar to progesterone.

MPA prevents ovulation—the release of an egg for fertilization—by suppressing the release of two hormones essential for the process: follicle-stimulating hormone (FSH) and luteinizing hormone (LH).

As an additional contraceptive action, the drug thickens cervical mucus, creating a barrier that limits sperm movement. It also thins the endometrial lining of the uterus, making it less likely for a fertilized egg to implant and grow into a viable pregnancy.

Beyond birth control, Depo-Provera is also used for treating endometriosis, menstrual irregularities, and other hormone-related conditions. By regulating hormone levels, Depo-Provera can reduce the frequency and severity of menstruation, which is particularly beneficial for women who experience intense pain, heavy bleeding, or other disruptive symptoms typical of menstruation.

How Is Depo-Provera Causing Brain Tumors?

Recent scientific findings, particularly the British Medical Journal (BMJ) study, have suggested a link between prolonged Depo-Provera use and an elevated risk of developing meningiomas–tumors that are typically non-cancerous and form in the protective layers surrounding the brain and spinal cord. 

The active ingredient in Depo-Provera, medroxyprogesterone acetate (MPA), is a synthetic version of the hormone progestogen. Studies have shown that it interacts with progesterone receptors on meningioma cells, potentially accelerating their growth. The interaction involves MPA binding with progesterone receptors – a process that promotes cellular activity within the meninges, potentially leading to abnormal tissue growth.

More Information About Meningiomas

Roughly 30% of all brain tumors are classified as meningiomas. Even though this type of tumor is typically considered benign, its location in the brain can lead to severe complications as it expands and places pressure on nearby brain structures and nerves. In extreme cases where they press against critical parts of the patient’s brain, meningiomas can become life-threatening.

Most meningiomas grow relatively slowly, a characteristic that makes early diagnosis difficult. However, some atypical and anaplastic (malignant) forms of meningioma grow more aggressively and exhibit higher recurrence rates.

The symptoms of a meningioma largely depend on its location, size, and growth rate, and typically include:

• Headaches
• Vision problems
• Seizures
• Hearing loss or tinnitus
• Cognitive impairment
• Personality changes

Types of Meningiomas and Related Treatment

Meningiomas are categorized based on their growth rate, cellular characteristics, and tendency to recur. The World Health Organization (WHO) classifies meningiomas into three grades, each reflecting its aggressiveness and potential impact on the patient.

1. Grade I (Benign) Meningiomas

• Characteristics: Grade I meningiomas are the most common and are usually considered benign. They grow slowly and often remain stable over time.
• Prognosis: These tumors typically have a favorable prognosis and a lower likelihood of recurrence. However, due to their location in the brain or spinal cord, they can still cause symptoms by pressing on surrounding structures.
• Symptoms: If the tumor size becomes significant or affects specific brain areas, patients may experience symptoms like headaches, vision problems, or seizures.
• Treatment: Observation or surgical removal is often effective, and radiation therapy is generally not required unless the tumor grows back.

2. Grade II (Atypical) Meningiomas

• Characteristics: Grade II meningiomas, also known as atypical meningiomas, exhibit a higher rate of cellular activity than benign types and may grow more quickly.
• Prognosis: These tumors have a higher risk of recurrence after treatment compared to Grade I. If they recur, they may show more aggressive behavior.
• Symptoms: Symptoms can be more pronounced and may worsen as the tumor grows. Symptoms can include neurological deficits, increased intracranial pressure, and cognitive impairment.
• Treatment: Treatment may involve a combination of surgery and radiation therapy, especially if the tumor cannot be completely removed surgically.

3. Grade III (Anaplastic or Malignant) Meningiomas

• Characteristics: Grade III meningiomas, also known as anaplastic or malignant meningiomas, are rare but highly aggressive. These tumors exhibit rapid growth and are highly likely to spread to other parts of the brain or spinal cord.
• Prognosis: Prognosis is often poor, as these tumors are challenging to control and tend to recur frequently, even after aggressive treatment.
• Symptoms: Symptoms may be severe due to the rapid growth and potential for widespread involvement, often causing significant neurological impairment.
• Treatment: Treatment typically includes aggressive surgical removal followed by radiation therapy. Chemotherapy may be considered in some instances, although it is generally less effective for meningiomas.

Depo-Provera and Bone Density Loss

While Depo-Provera’s impact on a user’s bone mineral density is not part of this lawsuit, it’s worth noting that the drug has a well-documented and widely recognized relationship with this severe side effect.

Since its initial release, numerous medical studies and user reports have revealed that prolonged use of Depo-Provera can increase the likelihood of losing bone density. This could lead to the patient developing osteoporosis, heightened risk of fractures, chronic pain, and reduced mobility.

The loss of bone density is attributed to the drug’s impact on the patient’s estrogen production. Healthy estrogen levels are essential for maintaining healthy bone tissue, and lower levels of the hormone can result in accelerated bone loss, particularly if the patient uses the drug for a prolonged period. 

Initial concerns about Depo-Provera’s impact on bone health emerged in the late 1990s when clinical studies highlighted a potential link between the drug and a reduction in bone density. A pivotal 2002 study published in the American Journal of Obstetrics & Gynecology reported that women using Depo-Provera for extended periods exhibited a measurable decrease in bone mineral density. 

User complaints have also been critical in bringing this specific side-effect to light. According to FDA records, numerous adverse event reports were submitted by users experiencing symptoms associated with reduced bone density.

These reports, combined with emerging clinical data, prompted the FDA in 2004 to require a “black box” warning for Depo-Provera. This was the FDA’s strongest warning level, indicating that the drug could cause irreversible loss of bone mineral density and advising consumers against using the drug for longer than two years.

Depo-Provera Lawsuit: Case Details and Background

Pfizer faces mounting legal challenges as plaintiffs claim the pharmaceutical company failed to adequately inform consumers about the potential connection between meningiomas and Depo-Provera.

Plaintiffs argue that Pfizer knew (or should have known) about these risks, given the volume of credible scientific literature and adverse event reports establishing the reasonable possibility of a link.

Product liability law in the United States holds companies responsible for ensuring that their products are safe when used as intended and for adequately warning consumers about known risks associated with use.

Plaintiffs and their legal teams will attempt to establish that Pfizer’s negligence constitutes the legal definition of “failure to warn.”

International Warnings 

Pfizer’s 2023 decision to issue brain tumor warnings outside the U.S. could become highly relevant in these lawsuits. In the European Union, the company has clearly highlighted the risk of developing meningiomas from prolonged Depo-Provera use, establishing that they are well aware of the risks.

Lawyers are likely to argue that this discrepancy proves that Pfizer was aware of the risks and acted with illegal negligence when they opted not to warn customers in the U.S. 

Pfizer’s Relationship with Generic Manufacturers and Liability Considerations

For plaintiffs, Pfizer’s involvement with generic versions of Depo-Provera adds a significant dimension to the case. If generic versions of the drug can be included in the lawsuit, it expands the scope of the claims and opens up new avenues for potential compensation. 

In most cases, when a brand-name drug becomes available in generic form, the company is no longer directly liable for the safety or warnings associated with the generic versions. Instead, responsibility typically shifts to the generic manufacturers. However, plaintiffs in the Depo-Provera lawsuits argue that Pfizer may still bear some accountability for the safety of the generic versions due to Pfizer’s unique involvement in their production and labeling.

This relationship between Pfizer and the manufacturers of generic Depo-Provera raises questions about whether Pfizer can distance itself from liability. Plaintiffs argue that because Pfizer continued to profit from the generic versions while maintaining a level of control, the company retained a duty to warn all users—both brand-name and generic—of known health risks.

Notable Depo Povera Lawsuits

Kristina Schmidt

Kristina Schmidt’s case, filed in October 2024 in the Northern District of California, is recognized as the first lawsuit linking Depo-Provera to brain tumors. 

Ms. Schmidt used Depo-Provera from 2005 to 2021. She was diagnosed with meningioma in June 2022 and underwent brain surgery later that year – a procedure that revealed additional complications that required significant surgical intervention. 

Lesley Noble

In October 2024, Lesley Noble filed a lawsuit in the Southern District of Indiana, alleging that her prolonged use of Depo-Provera led to the development of a meningioma. 

She began receiving injections in January 1995 and continued until October 2018. In July 2017, Ms. Noble underwent surgery to remove a meningioma and received radiation treatment in 2018 because of the tumor’s recurrence. 

Monique Jones

Monique Jones filed her lawsuit in October 2024 in the Central District of California. She began using Depo-Provera in 2000 at the age of 20 and continued until September 2024, receiving approximately 91 injections. 

Jones experienced symptoms such as lightheadedness, ear itching, headaches, vertigo, and blurred vision, leading to the discovery of an intracranial meningioma. Due to its calcified nature, surgical removal was not an option, leaving Ms.Jones facing the possibility of indefinitely needing to manage chronic pain and other symptoms.

Statutes of Limitations in Depo-Provera Lawsuits

Statutes of limitations determine the window period during which a plaintiff can file a lawsuit. The length of this window can vary considerably from one U.S. state to another, making legal guidance on this topic crucial.

For most Depo-Provera cases, the time limit often begins from the date the plaintiff discovers or reasonably should have discovered that their condition might be linked to Depo-Provera use. However, there are three legal concepts that influence a specific lawsuit’s discovery date. 

• The Discovery Rule: The Discovery Rule allows exceptions in cases where an injury isn’t immediately apparent. In cases involving Depo-Provera, plaintiffs argue that they only discovered the potential link between their brain tumors and the drug after recent scientific studies brought the risks to light. Because the long-term side effects weren’t immediately apparent, the clock on the statute of limitations may not have started until they learned of the possible connection. This rule can be especially beneficial for those diagnosed years after using the drug, as it grants them an extended filing period.
  
• Estoppel: In some cases, defendants’ actions can prevent them from using the statute of limitations as a defense. This principle, known as estoppel, applies if Pfizer or other entities made statements or took actions that misled plaintiffs into delaying their claims. For example, if Pfizer downplayed the risks of meningiomas or failed to disclose relevant safety information in a timely manner, plaintiffs could argue that they were prevented from filing sooner. Estoppel holds defendants accountable for behavior obstructing a plaintiff’s ability to act within the legal timeframe.
  
• Equitable Tolling: Equitable tolling may apply when circumstances beyond a plaintiff’s control prevent them from filing a claim on time. This could include severe illness, a lack of access to critical information, or being misled by conflicting medical or legal advice. Unlike estoppel, which focuses on the defendant’s conduct, equitable tolling addresses situations where the plaintiff faced significant external barriers to meeting the deadline. For Depo-Provera plaintiffs, this might involve not receiving timely notice of the risks or lacking resources to investigate potential claims.

Get Legal Support to Ensure You File On Time

Understanding how statutes of limitations and these legal doctrines apply to your case can be challenging. 

If you believe your health condition may be connected to Depo-Provera use and want to clarify your rights, Tosi Law is here to help. 

Contact us today for a free, no-obligation consultation.

Depo-Provera Lawsuit Compensation and Payouts

How Is Compensation for a Depo-Provera Lawsuit Calculated?

Compensation in Depo-Provera lawsuits typically aims to cover economic and non-economic damages plaintiffs have suffered. Economic damages include medical expenses—both past and future—such as costs associated with brain tumor diagnosis, surgery, or rehabilitation. Lost wages and diminished earning capacity are also likely to be considered.

Non-economic damages address the emotional toll and diminished quality of life resulting from health complications like meningiomas. In some cases, plaintiffs may also pursue punitive damages to hold Pfizer accountable for failing to warn consumers and to deter similar corporate negligence.

Who Is Eligible for Depo-Provera Compensation?

Eligibility hinges on proving that Depo-Provera use caused or contributed to a diagnosable condition, such as a meningioma. Plaintiffs must also demonstrate that they used the drug as prescribed and for a period sufficient to pose risks identified in scientific studies, typically a year or more.

What Size Payouts Are Expected for Depo-Provera Claims?

The size of payouts varies widely, depending on the severity of the plaintiff’s condition, the extent of their damages, and whether punitive damages are awarded. 

Early lawsuits, such as Kristina Schmidt’s case, may set benchmarks for potential settlements. As the litigation evolves, medical evidence, jury decisions, and the number of claims filed will likely influence compensation amounts.

Filing a Depo-Provera Claim

Establishing Your Eligibility for a Depo-Provera Lawsuit

To establish eligibility for a lawsuit, plaintiffs must present specific evidence that supports their claim. This includes:

• Medical Records: Verified documentation of Depo-Provera use over a prolonged period, particularly prescriptions or records of injections. These records are critical to establish exposure to the drug.
• Diagnosis Records: Medical confirmation of a meningioma or other adverse conditions potentially linked to Depo-Provera. Detailed physician notes, imaging results, and treatment plans help substantiate the claim.
• Timeline of Symptoms: A well-documented timeline showing when health issues began and evidence linking these issues to Depo-Provera use.

At Tosi Law, we provide free consultations to evaluate your eligibility and offer professional guidance on how to proceed with your case.

Contact us today.

Do I Need a Lawyer to Help Me File a Depo-Provera Claim?

While filing a lawsuit independently is possible, the complexity of product liability cases makes professional legal assistance invaluable. A lawyer ensures:

• Thorough Evidence Collection: Attorneys can subpoena records, work with experts, and navigate intricate legal requirements.
• Compliance with Legal Processes: Filing deadlines, procedural rules, and evidentiary standards are critical in these cases. A lawyer ensures everything is handled correctly.
• Maximized Compensation: Skilled attorneys negotiate with defendants to seek the highest possible settlement or, if necessary, represent clients effectively in court.

At Tosi Law, our attorneys specialize in pharmaceutical product liability cases. We combine legal expertise with personalized client care, ensuring your case receives the attention it deserves.

How Much Does It Cost to Hire a Depo-Provera Law Firm?

Tosi Law operates on a contingency fee basis, which means:

• No Upfront Costs: You won’t pay anything out of pocket to start your case.
• Payment Upon Success: We only collect a fee if we win or settle your case, aligning our success with yours.
• Transparent Terms: We’ll provide a clear outline of our fee structure during initial consultations and answer any questions you may have about this topic.

Our no-risk approach allows anyone affected by Depo-Provera’s health risks to seek justice, regardless of their financial situation.

How to Choose the Right Lawyer for Your Depo-Provera Lawsuit

Selecting the right lawyer not only influences the chances of your case being successful but it also impacts how potentially disruptive the case can be on your life. Without competent, empathetic, professional legal counsel, a lawsuit against a multinational organization like Pfizer can be very taxing on someone who is also experiencing health complications.

Don’t be shy to ‘look under the hood.’ Get to know your prospective partners. Examine their marketing material critically and ask important questions during initial conversations. Here are three things to look out for when you consider a law firm to represent you in your Depo-Provera case:

• Experience: Look for a firm with a track record of success in product liability cases involving pharmaceutical companies. The ideal law firm has a team with visible expertise in this legal arena. Ask questions about the partners and their involvement in cases like these.
• Resources: Cases against major corporations like Pfizer require substantial resources and access to medical experts, researchers, and litigators. Small firms may have a certain appeal, but assessing their capacity for investigation and complex administration is vital.
• Communication: A responsive and transparent legal team ensures you stay informed and involved throughout the process. It’s usually an excellent sign when all communication happens within the firm’s ecosystem. Be wary of lawyers who outsource their client contact teams to external vendors. 

At Tosi Law, we pride ourselves on combining industry-leading expertise with compassionate client service. We’ll guide you every step of the way, providing clear communication and a steadfast commitment to achieving the best possible outcome for your case.

Why Choose Tosi Law?

Tosi Law has a proven history of successfully handling product liability cases. With extensive experience in lawsuits involving defective medical devices and pharmaceuticals, our firm has developed a reputation for delivering results while offering highly personalized client service.

Our attorneys understand the challenges you’re facing and are ready to help. 

Contact Tosi Law today for a free, no-obligation consultation. Together, we’ll work to secure the compensation and justice you deserve.

Call Tosi Law if You Have Questions

If you or a loved one has developed multiple myeloma or any other type of cancer after being exposed to Roundup, you could be entitled to compensation. Please call Tosi Law LLP at 888-311-8292 for more information. Our defective product lawyers are ready to help you file a Roundup lawsuit.

Call Today

FAQs About the Depo-Provera Lawsuit

1. Does Depo-Provera cause brain tumors?

Research, including a major study published in the British Medical Journal, suggests that prolonged use of Depo-Provera is linked to an increased risk of meningiomas, which are typically non-cancerous brain tumors. While this association has not been conclusively proven, it has become a central issue in the lawsuits against Pfizer.

2. Who is eligible to file a Depo-Provera lawsuit?

Individuals who used Depo-Provera for an extended period and were later diagnosed with a meningioma or other severe health conditions potentially linked to the drug may be eligible. Eligibility typically depends on evidence of drug use, medical diagnosis, and the timeline of symptoms. Consulting a lawyer can clarify your eligibility.

3. What compensation can I seek in a Depo-Provera lawsuit?

Compensation can cover current and future medical expenses, lost wages, diminished quality of life, and emotional distress. In some cases, plaintiffs may also seek punitive damages to hold Pfizer accountable for negligence and deter future misconduct.

4. Is there a deadline for filing a Depo-Provera lawsuit?

Yes, statutes of limitations apply and vary by state. The filing period typically starts from the date of diagnosis or when the connection between Depo-Provera and your condition was reasonably discoverable. Acting quickly is crucial to ensure you meet legal deadlines.

5. Do I need to have used the brand-name Depo-Provera to file a lawsuit?

No, individuals who used generic versions of Depo-Provera may also qualify. However, establishing liability in such cases may involve unique legal considerations, which an experienced attorney can address.